Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Total Non-current Assets
All assets not expected to be converted to cash within one year.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 16.4% from a year ago
Total non-current assets stood at $12.9M at the end of Q1 FY2026, up 16.4% from a year earlier and down 7.0% from the prior quarter. Over 3 fiscal years it compounded at +245.9% a year.
Context
- Total non-current assets amounted to 2.6% of total assets at the end of Q1 FY2026, down 1.1 pp from a year earlier.
- Total non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +16.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 13.87M USD
- Year-over-year change
- +170.3%
- 3-year CAGR
- +245.9%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.87M | +170.3% |
| FY2024 | 2024-12-31 | 5.13M | +12.7% |
| FY2023 | 2023-12-31 | 4.55M | +1258.5% |
| FY2022 | 2022-12-31 | 335K | — |
Total Non-current Assets vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 total non-current assets of $12.9M is the 5th highest of the 10 companies compared; the peer median is $8.39M.
- Its year-over-year change of +16.4% is the 5th highest of 10, against a peer median of +1.7%.
- Total non-current assets amounts to 2.6% of total assets for RAPP, versus a peer median of 3.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $549.27M | +348.2% | +324.1% | 41.9% | |
| Sep 2026 | $525.73M | +106.7% | +84.6% | 29.3% | |
| Jun 2026 | $104.88M | +1.7% | +5.5% | 13.8% | |
| Mar 2026 | $91.56M | +588.3% | +176.1% | 21.9% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $12.9M | +16.4% | +245.9% | 2.6% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $8.39M | +36.8% | +57.2% | 3.2% |
| Mar 2026 | $7.13M | -15.0% | +62.2% | 2.6% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $4.41M | -1.3% | +1044.9% | 1.1% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $443K | -76.5% | -76.3% | 0.3% |
| Mar 2026 | $326K | -48.6% | -47.6% | 0.9% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | $8.39M | +1.7% | +62.2% | 3.2% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.